NASDAQ:ADRO - Aduro BioTech Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.20 -0.10 (-1.59 %)
(As of 09/23/2018 04:00 PM ET)
Previous Close$6.20
Today's Range$6.00 - $6.40
52-Week Range$5.10 - $11.55
Volume1.04 million shs
Average Volume321,424 shs
Market Capitalization$490.17 million
P/E Ratio-4.37
Dividend YieldN/A
Beta2.23
Aduro BioTech logoAduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer. Its products pipeline also comprises BION-1301, a B-select monoclonal antibody novel therapy for multiple myeloma; A PRoliferation-Inducing Ligand for the treatment of multiple myeloma, chronic lymphocytic leukemia, and colorectal carcinoma; CD27, a co-stimulatory receptor for the treatment of cancer; and CTLA-4 for the treatment of advanced melanoma and other cancers. The company's pLADD program is based on proprietary attenuated strains of Listeria that have been engineered to express tumor neo antigens that are specific to an individual patient's tumor. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Janssen Biotech, Inc, and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.

Receive ADRO News and Ratings via Email

Sign-up to receive the latest news and ratings for ADRO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADRO
CUSIPN/A
Phone510-848-4400

Debt

Debt-to-Equity RatioN/A
Current Ratio8.15
Quick Ratio8.15

Price-To-Earnings

Trailing P/E Ratio-4.37
Forward P/E Ratio-4.96
P/E GrowthN/A

Sales & Book Value

Annual Sales$17.24 million
Price / Sales28.43
Cash FlowN/A
Price / CashN/A
Book Value$3.07 per share
Price / Book2.02

Profitability

EPS (Most Recent Fiscal Year)($1.42)
Net Income$-91,860,000.00
Net Margins-574.11%
Return on Equity-44.97%
Return on Assets-22.52%

Miscellaneous

Employees162
Outstanding Shares79,060,000
Market Cap$490.17 million

Aduro BioTech (NASDAQ:ADRO) Frequently Asked Questions

What is Aduro BioTech's stock symbol?

Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO."

How were Aduro BioTech's earnings last quarter?

Aduro BioTech Inc (NASDAQ:ADRO) released its quarterly earnings results on Wednesday, August, 1st. The biotechnology company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.02. The biotechnology company earned $2.64 million during the quarter, compared to the consensus estimate of $3.74 million. Aduro BioTech had a negative net margin of 574.11% and a negative return on equity of 44.97%. View Aduro BioTech's Earnings History.

When is Aduro BioTech's next earnings date?

Aduro BioTech is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for Aduro BioTech.

What price target have analysts set for ADRO?

6 Wall Street analysts have issued 1-year price targets for Aduro BioTech's shares. Their predictions range from $6.00 to $30.00. On average, they expect Aduro BioTech's stock price to reach $14.80 in the next year. This suggests a possible upside of 138.7% from the stock's current price. View Analyst Price Targets for Aduro BioTech.

What is the consensus analysts' recommendation for Aduro BioTech?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aduro BioTech in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aduro BioTech.

What are Wall Street analysts saying about Aduro BioTech stock?

Here are some recent quotes from research analysts about Aduro BioTech stock:
  • 1. According to Zacks Investment Research, "Aduro has a broad, promising pipeline of novel immunotherapies under development for treatment of different forms of cancers. The company’s collaboration agreements with large pharma companies — Novartis and Johnson & Johnson — not only validate the company’s research platforms but also enhance its financial position, providing it with adequate funds. However, with no approved products in Aduro’s portfolio, the company heavily depends on funds generated from collaboration and license agreements, government grants as well as other payments for the development of its pipeline candidates. Thus, an inability to secure sufficient funding could hinder Aduro’s pipeline progress. Shares of the company have outperformed the industry in the year so far." (7/4/2018)
  • 2. Cantor Fitzgerald analysts commented, "ADRO shares are trading up modestly on the disclosure of a $3 million milestone from MRK’s (Merck, NC) initiation of a Phase I trial with the anti- CD27 candidate." (3/5/2018)
  • 3. HC Wainwright analysts commented, "All Three Platforms Now Clinical Stage; We Have High Expectations for B-Select Platform B-select investment starts bearing clinical stage candidates. Aduro announced the expected initiation of a Phase 1/2 clinical trial with its anti-APRIL antibody, BION-1301. This two part, open-label study, is being conducted in relapsed or refractory multiple myeloma patients (at least three prior systemic therapies). Once the recommended Phase 2 dose is identified in part 1, patients are to be expanded at the selected dose with the primary endpoint of overall response rate. The APRIL/BCMA pathway was also a hot topic at the recent ASH conference as an encouraging new target against myeloma. A proliferation inducing ligand (APRIL) is one of the main high affinity ligands that binds and activates BCMA resulting in a pro-survival cell signal. APRIL is a member of the TNF family and is overexpressed in patients with multiple myeloma (MM)." (12/13/2017)

Who are some of Aduro BioTech's key competitors?

Who are Aduro BioTech's key executives?

Aduro BioTech's management team includes the folowing people:
  • Mr. Stephen T. Isaacs, Chairman, CEO & Pres (Age 69)
  • Dr. Andrea van Elsas, Chief Scientific Officer (Age 51)
  • Mr. Blaine E. Templeman, Chief Legal Officer & Sec. (Age 52)
  • Ms. Jennifer Lew, Chief Financial Officer (Age 45)
  • Ms. Alexandra Santos, Exec. Director of Corp. Affairs & Investor Relations

When did Aduro BioTech IPO?

(ADRO) raised $119 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Who are Aduro BioTech's major shareholders?

Aduro BioTech's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.95%), FMR LLC (4.13%), Baillie Gifford & Co. (3.57%), Aquilo Capital Management LLC (2.54%), Citadel Advisors LLC (2.01%) and Harvard Management Co. Inc. (1.60%). Company insiders that own Aduro BioTech stock include Blaine Templeman, Dirk G Brockstedt, Elsas Andrea Van, Gregory W Schafer, Jennifer Lew, Natalie Sacks, Ross Haghighat, Stephen T Isaacs and Thomas W Dubensky. View Institutional Ownership Trends for Aduro BioTech.

Which major investors are selling Aduro BioTech stock?

ADRO stock was sold by a variety of institutional investors in the last quarter, including Harvard Management Co. Inc., Renaissance Technologies LLC, Alps Advisors Inc. and Alps Advisors Inc.. Company insiders that have sold Aduro BioTech company stock in the last year include Blaine Templeman, Dirk G Brockstedt, Elsas Andrea Van, Gregory W Schafer, Jennifer Lew, Natalie Sacks and Stephen T Isaacs. View Insider Buying and Selling for Aduro BioTech.

Which major investors are buying Aduro BioTech stock?

ADRO stock was purchased by a variety of institutional investors in the last quarter, including Aquilo Capital Management LLC, Citadel Advisors LLC, Baillie Gifford & Co., BlackRock Inc., FMR LLC, Northern Trust Corp, Vident Investment Advisory LLC and Centaurus Financial Inc.. View Insider Buying and Selling for Aduro BioTech.

How do I buy shares of Aduro BioTech?

Shares of ADRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aduro BioTech's stock price today?

One share of ADRO stock can currently be purchased for approximately $6.20.

How big of a company is Aduro BioTech?

Aduro BioTech has a market capitalization of $490.17 million and generates $17.24 million in revenue each year. The biotechnology company earns $-91,860,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. Aduro BioTech employs 162 workers across the globe.

What is Aduro BioTech's official website?

The official website for Aduro BioTech is http://www.aduro.com.

How can I contact Aduro BioTech?

Aduro BioTech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-848-4400 or via email at [email protected]


MarketBeat Community Rating for Aduro BioTech (NASDAQ ADRO)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  341 (Vote Outperform)
Underperform Votes:  167 (Vote Underperform)
Total Votes:  508
MarketBeat's community ratings are surveys of what our community members think about Aduro BioTech and other stocks. Vote "Outperform" if you believe ADRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel